Early Detection Research Network


This biomarker is also known as:
  • B7S1,
  • T-cell costimulatory molecule B7x,
  • VCTN1,
  • FLJ22418,
  • B7 superfamily member 1,
  • B7H4,
  • PRO1291,
  • Protein B7S1,
  • B7h.5,
  • B7 family member, H4,
  • B7X,
  • V-set domain containing T cell activation inhibitor 1,
  • Immune costimulatory protein B7-H4,
  • B7-H4,
  • OV110,
  • DD-0110,
  • VTCN1,


Highly glycosylated sialomucin; expressed on immune cells. Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation. Overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). Belongs to the B7 family of costimulatory proteins.


There are no datasets associated with this biomarker.

QA State: Accepted
Type: Protein

The following organs have data associated with this biomarker…


Phase: Three
QA State: Accepted


Genomic analysis revealed upregulation in breast and ovarian epithelial tumors; protein overexpression studies confirmed finding.

Performance Comment

Of the 28 ovarian cancer biomarkers tested in prediagnostic specimens, from the PLCO, CA125 remains the the single best biomarker for ovarian cancer and has its strongest signal within six months of diagnosis. B7-H4 alone was not a strong predictor.

Supporting Study Data

The following studies/protocols provide evidence supporting VTCN1 indications for the Ovary…

No supporting studies or protocols found.

Organ-Specific Protocols

No organ-specific protocols defined.

Organ-Specific Publications

Organ-Specific Resources

No organ-specific resources defined.

Version 5.0.2